L-Asparaginase
Phase 3Protein / enzyme
L-Asparaginase is one of 59 small molecule programs targeting Acute Lymphoblastic Leukemia. It is currently in Phase 3.
2
Indications
19
Total Trials
2
Active Trials
58
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
163 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Adriamycin
PfizerPhase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Oncaspar
SServier
Phase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Fludara
SanofiPhase 3
Medrol
PfizerPhase 3
Iclusig
TakedaPhase 3
Cellcept
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Lymphoblastic Leukemia9 trials
Show 6 more trials
Lymphoma5 trials
Adult Acute Lymphoblastic Leukemia2 trials
Acute Leukemia of Ambiguous Lineage1 trial
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT04440267·50 enrolled
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for L-Asparaginase. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company
- EERYtech Pharma